Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.58 |
| ▸ | CDK4 | P11802 | 7/20 | 0.55 |
| ▸ | CDK2 | P24941 | 5/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.55 |
| ▸ | CCND3 | P30281 | 3/20 | 0.55 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.55 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.51 |
| ▸ | CCND1 | P24385 | 4/20 | 0.50 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | STK17B | O94768 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28228708 | 0.88 | SYK (0.54) | SYKSTAT6CDK4CDK2CCNA2 | |
| SCHEMBL4492001 | 0.85 | SYK (0.62) | SYKSTAT6CDK4CDK2CCNA2 | |
| SCHEMBL5686069 | 0.81 | SYK (0.53) | SYKCDK4CCND1 | |
| SCHEMBL5686121 | 0.81 | SYK (0.64) | SYKCDK2CSF1RMAPK8MAPK9 | |
| SCHEMBL7064739 | 0.80 | SYK (0.60) | SYKSTAT6CDK4CDK2CCNA2 | |
| SCHEMBL4936386 | 0.80 | SYK (0.60) | SYKSTAT6CDK4CDK2CCNA2 | |
| SCHEMBL5686165 | 0.79 | FLT3 (0.56) | CDK4CDK2CDK6CCND1CSF1R | |
| SCHEMBL21275499 | 0.78 | PLK4 (0.57) | CDK4CDK2CCNA2CDK6ACVR1 | |
| SCHEMBL4499479 | 0.77 | SYK (0.67) | SYKSTAT6CDK4ACVR1JAK2 | |
| SCHEMBL572738 | 0.77 | ACVR1 (0.66) | ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1648464-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005009443-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | SYK 1151/4885STAT6 564/4885CDK4 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.